NO964200L - Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner - Google Patents

Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner

Info

Publication number
NO964200L
NO964200L NO964200A NO964200A NO964200L NO 964200 L NO964200 L NO 964200L NO 964200 A NO964200 A NO 964200A NO 964200 A NO964200 A NO 964200A NO 964200 L NO964200 L NO 964200L
Authority
NO
Norway
Prior art keywords
treatment
oral tolerance
autoimmune disease
enhancing cytokines
enhancing
Prior art date
Application number
NO964200A
Other languages
English (en)
Other versions
NO964200D0 (no
Inventor
Howard L Weiner
Youhai Chen
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO964200D0 publication Critical patent/NO964200D0/no
Publication of NO964200L publication Critical patent/NO964200L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fremgangsmåte for behandling av autoimmune sykdommer så som multippel sklerose i ved oral administrering av et tilstedeværende antigen så som myelinbasisk protein eller i proteolipid protein sammen med et ikke-interferon polypeptid som har Th2-forsterkende cytokin aktivitet på en slik måte at det induseres oral toleranse overfor tilstedeværende antigene som resulterer i suppressjon av den autoimmune responsen.
NO964200A 1994-04-08 1996-10-03 Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner NO964200L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US33252494A 1994-10-31 1994-10-31
PCT/US1995/004512 WO1995027500A1 (en) 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES

Publications (2)

Publication Number Publication Date
NO964200D0 NO964200D0 (no) 1996-10-03
NO964200L true NO964200L (no) 1996-10-03

Family

ID=26919544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964200A NO964200L (no) 1994-04-08 1996-10-03 Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner

Country Status (10)

Country Link
EP (1) EP0752879A4 (no)
JP (1) JPH09511990A (no)
KR (1) KR970702067A (no)
AU (1) AU695883B2 (no)
BR (1) BR9507452A (no)
CA (1) CA2187345A1 (no)
HU (1) HUT76101A (no)
IL (1) IL113301A0 (no)
NO (1) NO964200L (no)
WO (1) WO1995027500A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US6537810B1 (en) 1996-04-23 2003-03-25 President And Fellows Of Harvard College Methods for regulating T cell subsets by modulating transcription factor activity
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
CA2410563C (en) 2000-05-24 2013-04-23 John M. Hallenbeck Methods for preventing strokes by inducing tolerance to e-selectin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190750A (en) * 1990-03-09 1993-03-02 Asahi Kasei Kogyo Kabushiki Kaisha Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf
EP0563254B1 (en) * 1990-12-19 1995-11-08 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
EP0627933B1 (en) * 1992-02-28 2002-11-27 Autoimmune, Inc. Bystander suppression of autoimmune diseases
SK281806B6 (sk) * 1992-10-01 2001-08-06 Schering Corporation Použitie il-10 na prípravu liečiva na prevenciu diabetes mellitus
DE69305313T3 (de) * 1992-12-22 2001-06-21 Univ Cincinnati Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen

Also Published As

Publication number Publication date
NO964200D0 (no) 1996-10-03
EP0752879A4 (en) 1999-07-21
AU695883B2 (en) 1998-08-27
BR9507452A (pt) 1997-08-05
KR970702067A (ko) 1997-05-13
HUT76101A (en) 1997-06-30
EP0752879A1 (en) 1997-01-15
JPH09511990A (ja) 1997-12-02
AU2246795A (en) 1995-10-30
CA2187345A1 (en) 1995-10-19
HU9602751D0 (en) 1996-11-28
IL113301A0 (en) 1995-07-31
WO1995027500A1 (en) 1995-10-19

Similar Documents

Publication Publication Date Title
ATE228373T1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
NO964200L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
DE68924162D1 (de) Stressproteine und verwendungen dafür.
DK0689449T3 (da) Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin
DE69634266D1 (de) Epitope von diphtheriatoxin
EP0663836A1 (en) TREATMENT OF AUTOIMMUNE AND INFLAMMATION DISEASES.
EP0305967A3 (en) Conjugates of cytokines with immunoglobulins
NO931372L (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
EP0726758A4 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTHES TARGETED AGAINST THE HEPATITIS B-VIRUS
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
DE69519856T2 (de) Expression von albumin in hefe
DK447684A (da) Homogent immuninterferon
HK1025738A1 (en) Lo-cd2a antibody and uses thereof for inhibiting tcell activation and proliferation
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE68928710D1 (de) T-Zellen-Wachstumsfaktor
IL113280A0 (en) Method of treating auto-immune diseases using type one interferons
DE69636527D1 (de) Antigenes protein aus malassezia
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
EP0642333A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH IMMUNOLOGICAL DYSFUNCTION.
DK0959899T3 (da) LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation
RU92008227A (ru) Способ улучшения настроения и самочувствия
CA2133995A1 (en) Method and composition for the treatment of disorders involving immunological dysfunction

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application